WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events:
- TD Cowen 7th Annual Virtual Fall Oncology Innovation Summit on November 3 at 2:00 p.m. ET;
- UBS Biopharma Conference in Miami, FL on November 8 at 10:30 a.m. ET;
- Stifel 2023 Healthcare Conference in New York, NY on November 15 at 2:25 p.m. ET;
- Piper Sandler 35th Annual Healthcare Conference in New York, NY on November 28 at 12:30 p.m. ET; and
- Evercore ISI 6th Annual HealthCONx Conference in Miami, FL on November 29 at 12:30 p.m. ET.
Live webcasts of the fireside chats will be available under the "Events and Presentations" section of the Investors page on the Company's website at www.kymeratx.com. Replays of the webcasts will be archived and available following the event.
In addition, the Company will host one-on-one meetings at the J.P. Morgan Equity Opportunities Forum in Miami, FL on November 7, 2023, and the Truist Securities BioPharma Symposium in New York, NY on November 9, 2023. The Company will also participate on a panel at the Truist Symposium entitled, Advancing Therapeutics Across I&I Indications.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera's Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body's innate protein recycling machinery to degrade ...